Related references
Note: Only part of the references are listed.
Article
Immunology
Kathrine Agergard Kaspersen et al.
Summary: The study shows that the infection fatality rate (IFR) of healthy individuals under 51 years old without comorbidities is very low. However, the IFR increases with age and comorbidity. Additionally, there was a decline in IFR from the first to the second wave of the epidemic.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Biochemistry & Molecular Biology
Clare Smith et al.
Summary: A clinical review of all pediatric deaths in England from March 2020 to February 2021 attributes 25 deaths to SARS-CoV-2 infection and identifies risk factors to guide interventions. These results are important for guiding decisions on shielding and vaccinating children, with factors like age, ethnicity, and comorbidities potentially influencing mortality rates related to SARS-CoV-2.
Article
Immunology
Nigel Garrett et al.
Summary: We report a 23% asymptomatic SARS CoV-2 Omicron carriage rate in participants of a clinical trial in South Africa, which is 15 times higher than in previous trials. We also found a strong correlation between lower CD4( + )T-cell counts in HIV-infected individuals and increased odds of being SARS-CoV-2 PCR positive.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Environmental Sciences
Stefan Pilz et al.
Summary: Seroprevalence surveys indicate that a significant proportion of the global population has been infected with SARS-CoV-2, and natural immunity plays a crucial role in protecting against reinfections and severe disease. National surveys show that previous infection provides a reduced risk of reinfection for at least one year, with moderate waning immunity. Natural immunity appears to have similar effectiveness against different SARS-CoV-2 variants, except for the Omicron variant which requires further study. Observational studies suggest that natural immunity may provide equal or greater protection compared to two doses of mRNA vaccines, although data are not consistent. Combining previous infection with vaccination seems to offer the greatest protection against SARS-CoV-2, but there are still knowledge gaps in this area.
ENVIRONMENTAL RESEARCH
(2022)
Editorial Material
Medicine, General & Internal
John P. A. Ioannidis
Summary: There is no quantitative definition widely accepted for the end of a pandemic like COVID-19. The end of the pandemic and transition to endemicity may be based on a high proportion of the global population having immunity from natural infection or vaccination. By the second half of 2021, it is likely that 70% of the global population has been vaccinated or infected. While outbreaks may continue to occur, they are expected to have less severe impact. Death toll and occupancy rates in ICUs also indicate a transition to endemicity by the end of 2021 or early 2022. The personal risk for most people globally is already very low, but perceived risk may still be exaggerated. Many countries continue to implement stringent restrictive measures. The attention from media and scientific circles should be tempered. Public health officials need to declare the end of the pandemic.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
Editorial Material
Medicine, General & Internal
Helene Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Editorial Material
Medicine, General & Internal
Govind Persad et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Sivan Gazit et al.
Summary: This study examined the effectiveness of a fourth dose of the Pfizer-BioNTech mRNA vaccine compared to three doses over a 10-week period. The results showed that the fourth dose provided additional protection against SARS-CoV-2 infection and severe COVID-19 disease in the first three weeks. However, the relative effectiveness of the fourth dose against infection decreased over time.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
John P. A. Ioannidis
Summary: Non-randomised studies assessing COVID-19 vaccine effectiveness need to consider multiple factors that may generate spurious estimates due to bias or genuinely modify effectiveness. Steps and measures to consider for improving vaccine effectiveness estimation include registration of studies, sharing of raw data and code, blinded assessment of outcomes, and better communication with both relative and absolute metrics of risk reduction.
BMJ EVIDENCE-BASED MEDICINE
(2022)
Review
Medicine, General & Internal
Maria Elena Flacco et al.
Summary: This meta-analysis study suggests that the risk of SARS-CoV-2 reinfections is relatively low, but has increased during the first three months of the Omicron wave. There is a strong natural immunity following primary infection, which may last for more than one year. The risk and healthcare needs of recovered individuals might be limited.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Medicine, General & Internal
Ramandip Grewal et al.
Summary: This study estimated the marginal effectiveness of a fourth dose compared to a third dose of mRNA covid-19 vaccines and the vaccine effectiveness of BNT162b2 and mRNA-1273 vaccines against the omicron variant. The results showed that a fourth dose improved protection against infection, symptomatic infection, and severe outcomes. Vaccine effectiveness increased with each additional dose.
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
Matan J. Cohen et al.
Summary: Despite high vaccination rates among health care workers in Israel, a significant number of breakthrough infections were observed during the Omicron wave. A fourth vaccine dose was recommended to mitigate the infection rate. This study found that the fourth dose of the vaccine reduced breakthrough infection rates among hospital staff, although not as much as the third dose.
Article
Leon Peto et al.
Advances in Biological Regulation
(2022)
Article
Public, Environmental & Occupational Health
Hiam Chemaitelly et al.
Summary: The duration of immunity provided by natural infection of SARS-CoV-2 diminishes over time and may disappear within a few years, with viral immune evasion accelerating this process. However, protection against severe reinfection remains very strong, regardless of the variant, for over 14 months after the primary infection.
JOURNAL OF TRAVEL MEDICINE
(2022)
Review
Medicine, General & Internal
Dan H. Barouch
Summary: This article reviews the protective effects of vaccination and prior infection on severe Covid-19, and proposes future research directions.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Dan-Yu Lin et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Joao Malato et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Alexandra Savinkina et al.
Summary: Universal vaccination in low-income and lower-middle-income countries would avert an estimated 1.5 million COVID-19 deaths with a total cost of US$61 billion and a cost-per-COVID-19 death averted of approximately US$40,800.
Article
Immunology
Ronen Arbel et al.
Summary: The study evaluated the health and economic outcomes of lockdowns and vaccination campaigns to combat COVID-19. Both the first and second lockdowns, as well as the primary vaccination campaign, effectively prevented COVID-19 deaths. However, the cost per prevented COVID-19 death is significantly lower with effective vaccination compared to a national lockdown.
Article
Pediatrics
Ian Kracalik et al.
Summary: This study investigated the long-term clinical outcomes and quality of life in individuals with myocarditis after mRNA COVID-19 vaccination. The findings showed that most patients were considered recovered by healthcare providers at least 90 days after the onset of myocarditis, and their quality of life was comparable to pre-pandemic and early pandemic populations of a similar age.
LANCET CHILD & ADOLESCENT HEALTH
(2022)
Article
Health Care Sciences & Services
Snezana Medic et al.
Summary: As of January 31, 2022, SARS-CoV-2 reinfections were uncommon until the end of 2021 but became common with the advent of the Omicron variant. Most reinfections were mild. Boosters may modestly reduce reinfection risk.
LANCET REGIONAL HEALTH-EUROPE
(2022)
Article
Health Care Sciences & Services
Christian Erikstrup et al.
Summary: The Omicron variant caused a surge in SARS-CoV-2 infections in Denmark despite high vaccination coverage. Using blood donor serosurveillance, the study estimated the percentage of recently infected individuals in the background population and found that one third of infections were missed by PCR testing. The infection fatality rate was lower than previous waves.
LANCET REGIONAL HEALTH-EUROPE
(2022)
Letter
Immunology
Jackie Kleynhans et al.
Summary: After the third wave of COVID-19 infections in South Africa, seroprevalence in a rural community reached 60%, while in an urban community it reached 70%. The high seroprevalence before the emergence of the Omicron variant may have contributed to the reduced illness severity observed in the fourth wave.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Health Care Sciences & Services
Moshe Yanovskiy et al.
Summary: This study conducted an ethical analysis of cost-effectiveness analysis (CEA) and concluded that CEA is not only a practical necessity but also an ethical necessity. Using three independent methods, it determined the cost-effectiveness threshold (CET) to be around 1.0 +/- 0.4 gross domestic product per capita (GDPpc) per quality-adjusted life-year. Therefore, it suggests that 140% of GDP per capita per quality-adjusted life-year should be considered as the upper limit of prudent and ethically justified expenditure on life extension programs.
INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING
(2022)
Article
Medicine, General & Internal
Yair Goldberg et al.
Summary: This study used data from the Israeli Ministry of Health database to compare the rate of infection with the time since immunity-confering events. The results showed that the protection against reinfection decreased over time for individuals who had previously been infected or vaccinated, but it was still higher than the protection conferred after the same time had elapsed since the second dose of vaccine among those who were previously uninfected. A single dose of vaccine after infection reinforced protection against reinfection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Health Care Sciences & Services
Peter Nordstrom et al.
Summary: This study examined the impact of a fourth dose of COVID-19 vaccine on the risk of death, finding that the fourth dose significantly reduced the risk of death in residents of long-term care facilities and individuals aged 80 and older in the first two months, but the protection slightly decreased over time.
LANCET REGIONAL HEALTH-EUROPE
(2022)
Article
Medicine, General & Internal
Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jennie S. Lavine et al.
Summary: The study suggests that infection-blocking immunity to SARS-CoV-2 wanes rapidly while disease-reducing immunity is long-lived. The model predicts that once reaching endemic phase, SARS-CoV-2 may become no more virulent than the common cold. However, a different outcome is predicted for an emergent coronavirus causing severe disease in children.
Article
Medicine, General & Internal
Stefan Pilz et al.
Summary: According to the study in Austria, the rate of SARS-CoV-2 re-infections is relatively low. Protection against SARS-CoV-2 after natural infection is comparable to the highest estimates of vaccine efficacies.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Cardiac & Cardiovascular Systems
Pratyaksh K. Srivastava et al.
Article
Surgery
CC Miller et al.
EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY
(2004)
